2019
Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment
Benchetrit L, Torabi SJ, Tate JP, Mehra S, Osborn HA, Young MR, Burtness B, Judson BL. Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment. Oral Oncology 2019, 94: 32-40. PMID: 31178210, DOI: 10.1016/j.oraloncology.2019.05.009.Peer-Reviewed Original ResearchConceptsChemotherapy clinical trialsNational Cancer DatabaseClinical trialsDefinitive radiotherapyChemotherapy administrationNational Comprehensive Cancer Network guidelinesMultivariable logistic regression analysisNeck squamous cell carcinomaEnd Results ProgramSquamous cell carcinomaClinical trial participationLogistic regression analysisGeneral U.S. populationChemotherapy useDefinitive chemoradiotherapyNCCN guidelinesAdult patientsDefinitive treatmentMultivariable analysisNetwork guidelinesResults ProgramCell carcinomaTrial participationCancer DatabaseU.S. patientsPTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma
Eze N, Lee JW, Yang DH, Zhu F, Neumeister V, Sandoval-Schaefer T, Mehra R, Ridge JA, Forastiere A, Chung CH, Burtness B. PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. Oral Oncology 2019, 91: 69-78. PMID: 30926065, PMCID: PMC6855599, DOI: 10.1016/j.oraloncology.2019.02.026.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaEpidermal growth factor receptorSquamous cell carcinomaCell carcinomaCetuximab-based therapyTrial of cisplatinTrials (RCTs) of cetuximabPotential predictive biomarkersPTEN expressionLack of benefitPI3K mutationsPI3K p110αHigh PTEN expressionPI3K pathwayGrowth factor receptorHot spot mutationsStandard therapySuperior PFSMultivariable analysisPredictive biomarkersLoss of expressionSuch therapyCommon abnormalityCetuximabSide effects
2017
Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival
Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival. Journal Of The National Cancer Institute 2017, 109: djx042. PMID: 28521361, DOI: 10.1093/jnci/djx042.Peer-Reviewed Original ResearchConceptsEarly-stage glottic cancerOverall survivalGlottic cancerMultivariable Cox proportional hazards regressionNational Comprehensive Cancer Network guidelinesNational Cancer Data BaseCox proportional hazards regressionPropensity scoreClinical T1 diseaseImproved overall survivalHigh-volume centersProportional hazards regressionLog-rank testPatterns of careRadiation treatment schedulesLarge national databaseCT2 diseaseDefinitive radiotherapyT1 diseaseHypofractionated radiotherapyImproved survivalMultivariable analysisTreatment patternsHazards regressionNetwork guidelines
2013
Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B. Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers. Clinical Cancer Research 2013, 19: 6633-6643. PMID: 24088734, PMCID: PMC4045641, DOI: 10.1158/1078-0432.ccr-13-0152.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, WesternCarcinoma, Squamous CellCombined Modality TherapyCyclin-Dependent Kinase Inhibitor p16DNA RepairDNA-Binding ProteinsEndonucleasesFemaleHead and Neck NeoplasmsHeLa CellsHumansImmunoprecipitationKaplan-Meier EstimateMaleNeoplasm Recurrence, LocalRetrospective StudiesTissue Array AnalysisTreatment OutcomeConceptsMedian survivalExcision Repair Cross-Complementing Group 1Low ERCC1 expressionSquamous cell headKaplan-Meier curvesSquamous cell carcinomaCisplatin-based therapyLonger median survivalERCC1 protein expressionInitial tumor presentationAdjuvant radiotherapyMultimodality treatmentRecurrent diseaseInitial presentationMultivariable analysisRecurrent cancerTumor presentationCell carcinomaHuman papillomavirusERCC1 expressionNeck cancerSurvival differencesCell headArchival tumorsGroup 1
2012
Effect of increased time from chemoradiation to surgery on the pathologic complete response rate in patients with esophageal cancer.
Shaikh T, Ruth K, Scott W, Burtness B, Cohen S, Konski A, Cooper H, Astsaturov I, Meyer J. Effect of increased time from chemoradiation to surgery on the pathologic complete response rate in patients with esophageal cancer. Journal Of Clinical Oncology 2012, 30: 84-84. DOI: 10.1200/jco.2012.30.4_suppl.84.Peer-Reviewed Original ResearchPathologic complete responseEsophageal cancerPathologic complete response rateT3/T4 lesionsT1/T2 lesionsCarboplatin-based therapyTri-modality treatmentComplete response rateMedian radiation doseType of chemotherapyResectable esophageal cancerMultivariable logistic regressionSquamous cell carcinomaRadiation doseEnd of chemoradiationTrimodality therapyDistant recurrenceSubsequent surgeryT4 lesionsComplete responseMedian ageRectal cancerT2 lesionsMedian timeMultivariable analysis